Long-term effects of intermittent androgen suppression therapy on lean and fat mass: a 33-month prospective study-Reference-Cited by-同舟云学术

Long-term effects of intermittent androgen suppression therapy on lean and fat mass: a 33-month prospective study

Published:2012-08-21 Issue:1 Volume:16 Page:67-72
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Spry N A,Taaffe D R,England P J,Judge J S,Stephens D A,Peddle-McIntyre C,Baker M K,Newton R U,Galvão D A

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

http://www.nature.com/articles/pcan201233.pdf

Reference42 articles.

1. Moyad MA . Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol 2005; 23: 56–64.

2. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS . Risk of the ‘androgen deprivation syndrome’ in men receiving androgen deprivation for prostate cancer. Arch Intern Med 2006; 166: 465–471.

3. Kaisary AV . Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer. Prostate Cancer Prostatic Dis 2005; 8: 140–151.

4. McCredie M, Cox B . Prostate-specific antigen testing for prostate cancer: the case for informed consent. Med J Aust 1998; 169: 9–10.

5. Moul JW . Prostate specific antigen only progression of prostate cancer. J Urol 2000; 163: 1632–1642.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Au/Doc/Quer@PDA/A10-3.2 Nanoparticles for targeted treatment of docetaxel-resistant prostate cancer;Journal of Biomaterials Science, Polymer Edition;2024-05-20

2. Skeletal Muscle Function Is Altered in Male Mice on Low-Dose Androgen Receptor Antagonist or Estrogen Receptor Agonist;Endocrinology;2023-08-26

3. Low skeletal muscle mass is clinically underestimated in advanced metastatic prostate cancer: the cross-sectional SCAN study;BMJ Supportive & Palliative Care;2022-09-13

4. UPDATE – Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies (Full-text);Canadian Urological Association Journal;2022-07-21

5. A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND);Prostate Cancer and Prostatic Diseases;2022-03